Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: A retrospective cohort-based analysis using the THIN database

British Journal of Diabetes and Vascular Disease

Volumn 10, Issue 4, 2010, Pages 178-182

  Evans, Marc L ^a   Sharplin, Peter ^b   Owens, David R ^c   Chamberlain, George H ^b   Longman, Andrea J ^b   McEwan, Philip ^b  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b CRC Limited   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Glycaemic control; HbA1C; Insulin initiation; Oral hypoglycaemic agents; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; DATA BASE; DRUG UTILIZATION; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RETROSPECTIVE STUDY; UNITED KINGDOM;

EID: 77957138773     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651410370659     Document Type: Article

References (22)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glu-cose control with sulphonylureas or insulin compared with conven-tional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
2. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the development and pro-gression of long term complications in insulin dependent diabetes N Engl J Med 1993;329:978-86
4. The Diabetes Control and Complications Trial/Epidemiology of Diabetes nterventions and Complications (DCCT/EDIC) Study Research Group ntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
5. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32 193-203
6. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
7. The ADvAnCE Collaborative Group. Intensive blood glucose contro and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
8. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129-39
9. Department of Health. Quality and Outcomes Framework (QOF), 2009 http://www.dh.gov.uk/en/Healthcare/Primarycare/Primarycarecontracting/ QOF/index.htm (Accessed 11 november 2009)
10. Turner RC, Cull CA, Holman RR. Glycemic control with diet, sulfonylurea, metformin and insulin in patients with type 2 diabetes. Progressive requirement for multiple therapies. UKPDS 49. JAMA 1999;281:2005-12
11. Brown, JA, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-40
12. Rubino A, McQuay LJ, Gough SC et al. Delayed initiation of subcutane-ous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK Diabet Med 2007;24:1412-18
13. Krentz AJ, bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411
14. Poole CD, Tetlow T, McEwan P et al. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general prac-tice in the UK: A retrospective database analysis. Curr Med Res Opin 2007;23(suppl 1):S41-8
15. Currie CJ, Poole CD, Tetlow T et al. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis. Curr Med Res Opin 2007;23(suppl 1):S33-9.
16. Pinheiro J, Bates DM. Mixed Effects Models in S and S-PLUS. new York Springer-verlag, 2000
17. National Institute of Health and Clinial Excelence. Diabetes, Type 2 diabetes: blood glucose. London: NICE, 2002. http://www.nice.org.uk/ Guidance/G (Accessed 3 September 2009)
18. National Institute of Health and Clinial Excelence. Diabetes, Type 2 (update). London: NICE 2008. http://www.nice.org.uk/Guidance/ CG66 (Accessed: 3 September 2009)
19. BMA. QOF Changes and new indicators for 2009/10. London: BMA, 2008. http://www.bma.org.uk/employmentandcontracts/independ-ent-contractors/ quality-outcomes-framework/QoFchangesOct08.jsp (Accessed 3 September 2009)
20. Peyrot M, Rubin RR, Lauritzen T et al. Resistance to insulin therapy among patients and providers. Diabetes Care 2005;28:2673-9
21. Surwit RS, Van Tilburg MAL, Parekh PI et al. Treatment regimen deter-mines the relationship between depression and glycemic control Diabetes Res Clin Practice 2005;69:78-80
22. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65